Brian Skorney

James Condulis

Kristen Kluska

Leland Gershell

Yale Jen

Yasmeen Rahimi

Debjit Chattopadhyay

Myriam Belghiti

Rye Forseth

Tyler Van Buren

Ry Forseth

- Gibbs Mura is investigating a potential **securities class action lawsuit** against Soleno Therapeutics, Inc. (SLNO).  **[1484565_81dc594bbd9c4594af6fb380c0352d35_0]** 
- The investigation follows a **Scorpion Capital report** released on **August 15, 2025**, alleging serious safety concerns with Soleno's Prader-Willi Syndrome treatment, VYKAT XR, including reports of children hospitalized for potential heart failure, and claims of "sham" clinical trials.  **[1484565_81dc594bbd9c4594af6fb380c0352d35_0]** 
- Soleno's stock fell **over 8%** on **August 15, 2025**, after the Scorpion Capital report.  **[1484565_81dc594bbd9c4594af6fb380c0352d35_0]** 
- Shares fell an additional **over 12%** on **September 10, 2025**, after Soleno disclosed a **patient death** involving VYKAT XR.  **[1484565_81dc594bbd9c4594af6fb380c0352d35_0]**

Soleno Therapeutics Faces Investigation Amid Drug Safety Concerns and Patient Death

- Soleno Therapeutics has **recently launched VICAT XR** in the US for Prader Willi syndrome (PWS) following its approval, and has also filed in Europe.  **[1484565_tx_380332_0]** 
- The US commercial launch achieved **646 patient start forms** and **295 prescribers** in Q2, covering **100 million lives** by the end of Q2.  **[1484565_tx_380332_0]** **[1484565_tx_380332_3]** 
- The company is in a **very strong financial situation** after completing a raise in July 2025, which enables aggressive investment in Europe and future life cycle initiatives.  **[1484565_tx_380332_5]** 
- VICAT XR's benefits include **improvements in hyperphagia** and other PWS behaviors, with manageable side effects like hyperglycemia and peripheral edema that typically appear in the first few months.  **[1484565_tx_380332_1]** **[1484565_tx_380332_2]** **[1484565_tx_380332_3]**

Soleno Therapeutics Discusses VICAT XR Commercial Launch and Financials

- On **August 15, 2025**, Soleno Therapeutics, Inc. (SLNO) shares experienced a significant drop after **Scorpion Capital** published a highly critical report.  **[1484565_6dde74f47e71484ca50dc790609c2418_0]** 
- **Hagens Berman**, a national shareholders rights firm, has opened an investigation into Soleno, probing whether the company misled investors about the safety and commercial prospects of its drug, **VYKAT™ XR**.  **[1484565_6dde74f47e71484ca50dc790609c2418_0]** 
- Scorpion Capital's report alleged that **VYKAT™ XR** could be at risk of market withdrawal or plunging new prescriptions due to reports of children hospitalized for potential heart failure, described Soleno as a "**one-trick pony**" with its core patent set to expire in **2026**, and raised concerns about "hocus-pocus" launch metrics and data integrity issues related to a "controversial physician".  **[1484565_6dde74f47e71484ca50dc790609c2418_0]**

Soleno Therapeutics Faces Investigation Following Critical Report

SOLENO THERAPEUTICS (SLNO)